Kashyap Patel: Using the EpiSwitch CIRT Test to Assess the Likelihood of Response to Immunotherapy
Kashyap Patel, Past President at Community Oncology Alliance, shared a post on LinkedIn, about a recent article he and his colleagues co-authored, published in Cancers:
“Immunotherapy has significantly transformed the management of various solid tumors, including melanoma and other indications for cancer patients.
Despite its advancements, oncologists still lack a definitive positive predictive test to determine the best treatment option for each patient.
In collaboration with Oxford Biodynamics, we conducted a prospective, evidence-based study using the EpiSwitch CIRT test to assess the likelihood of response to immunotherapy.
We are thrilled to announce the publication of our findings in a peer-reviewed journal.”
Title: Clinical Utility of the EpiSwitch CiRT Test to Guide Immunotherapy Across Solid Tumors: Interim Results from the PROWES Study
Authors: Joe Abdo, Joos Berghausen, Ryan Mathis, Thomas Guiel, Ewan Hunter, Robert Heaton, Alexandre Akoulitchev, Sashi Naidu, Kashyap Patel
Read the Full Article on Cancers
More posts featuring Kashyap Patel.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023